Tuesday, March 18, 2008

MabVax Therapeutics Raises $8M For Cancer Treatment

San Diego-based MabVax Therapeutics has recently raised $8M in a Series A funding round, from GBP Capital. The firm is focused on development and commercialization of immunotherapies for the treatment of cancer. According to MabVax, the firm's technology is based on work on monovalent cancer vaccines at the Memorial Sloan-Kettering Cancer Center, which has licensed the technology to MabVax. More information »